Why Bristol-Myers Squibb is making a big bet its approach to treating lung cancer is the right one (MRK, BMY)

A new batch of data on Monday showed how immunotherapy, a new kind of cancer treatment that harnesses the body’s immune system, works in lung cancer patients. Among the data were results on how Bristol-Myers Squibb’s combination of two immunotherapy drugs compared to traditional chemotherapy in a certain group of lung cancer patients. While the results were positive, BMS closed on Monday down 7.7%.  BMS’s head of oncology Fouad Namouni told Business Insider why

Continue reading...